Updated on 3 July 2012
How will you promote Vibact IBS in India?
Mr Sukumar: Our understanding of the market situation is that irritable bowel syndrome has not been well understood, as a consequence of which various symptoms, such as bloating, abdominal pain, flatulence, constipation, are treated separately. It will be our endeavor to bring about awareness amongst doctors to identify patients presenting themselves with various symptoms of irritable bowel syndrome and give them a treatment that addresses this set of symptoms in its entirety.
We will create awareness amongst doctors about benefits that will accrue to their patients with IBS, by use of Lactobacillus plantarum 299v in preference to other products. This will enable us to establish Vibact-IBS as a key treatment option for doctors.
Share with us the main highlights of the agreement with USV India.
Mr Oredsson: USV has a lot of experience in the probiotic field and already offers the market-leading probiotic prescription brand Vibact in India. Vibact IBS will strengthen the USV portfolio, specifically targeting IBS and IBS-related symptoms. When combining USV's strong market knowledge and field force with Probi's effective product and scientific knowledge, we build the base for a strong partnership. Probi and USV will work together to secure a successful launch.
What is the market size of probiotic-based product in India? What will the price of the product in India?